Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported net revenues of $21.6 million for Q1 2022, significantly up from $914,000 in Q1 2021, driven by strong demand for LUPKYNIS following its FDA approval in January 2021. The company maintains its revenue guidance of $115-$135 million for 2022, reflecting a growth of over 150-200% compared to 2021. Despite a net loss of $37.6 million for the quarter, improvements in patient start forms and an upcoming EMA review for LUPKYNIS are promising milestones. Aurinia's cash reserves stood at $418.8 million as of March 31, 2022.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced a change to the dial-in numbers for its first-quarter financial and operational results conference call on May 10, 2022. The updated numbers are (866) 682-6100 / (862) 298-0702 for U.S. and Canada participants. Additionally, an audio webcast will be accessible via the 'Investors' section on Aurinia's website, with a replay available following the event. Aurinia is known for its FDA-approved oral therapy for treating active lupus nephritis, focusing on serious diseases with high unmet medical needs.

Aurinia Pharmaceuticals (NASDAQ: AUPH) will announce its financial and operational results for Q1 2022 on May 10, 2022, before the market opens. The management team will conduct a conference call/webcast at 8:30 am ET to discuss the results and provide a business update. Interested parties can participate by dialing +1-877-407-9170 or accessing the audio webcast via Aurinia’s corporate website. Aurinia is dedicated to developing therapies for serious diseases, having introduced the first FDA-approved oral treatment for lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is sponsoring charitable grants to expand community-focused patient navigator programs for individuals with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This initiative aims to eliminate care barriers, particularly in underserved populations. Grants of up to $50,000 will be awarded to U.S.-based organizations to enhance patient education and access to treatment. In its first year, Aurinia distributed $250,000 to five programs, showing significant improvements in patient care and adherence.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced new analyses of LUPKYNIS™ (voclosporin) to be presented at the 2022 National Kidney Foundation Spring Clinical Meetings in Boston from April 6-10, 2022. The studies aim to expand the understanding of LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis. Presentations will include findings on the drug's efficacy, a prospective observational registry, and improvements in disease impact. The research underscores Aurinia's commitment to autoimmune disease therapeutics.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its executive management team's participation in two investor conferences. The Cowen 42nd Annual Virtual Healthcare Conference is scheduled for March 9, 2022, at 2:50 p.m. ET, while the Oppenheimer’s 32nd Annual Healthcare Conference will take place on March 16, 2022, at 1:20 p.m. ET. Interested parties can access the live webcasts on the Aurinia corporate website under the Investors section.

Aurinia is focused on treating serious diseases, having launched LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a 60% increase in Q4 2021 net revenue to $23.4 million and a full-year revenue of $45.6 million. The company achieved notable growth in LUPKYNIS patient starts and maintained a strong cash position of $466.1 million as of December 31, 2021. For 2022, Aurinia projects net revenue guidance of $115-$135 million, driven by positive results from the AURORA 2 study. With confirmed payor coverage exceeding 90% in the U.S., Aurinia is well-positioned for ongoing progress amid a robust product launch.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its fourth quarter and year-end 2021 financial results on February 28, 2021, before markets open. A conference call/webcast will be held at 8:30 am ET to discuss the results and the company's outlook for 2022. Aurinia focuses on therapies for serious diseases with high unmet needs, having launched the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced its participation in the 11th Annual Leerink Global Healthcare Conference, scheduled from February 14-18, 2022. The company's corporate presentation will take place virtually on February 16, 2022, at 8 am ET. Interested participants can listen to the presentation by registering through a public link or by visiting the Investor section of Aurinia's corporate website. Aurinia is focused on developing therapies for serious diseases with high unmet medical needs, notably introducing the first FDA-approved oral therapy for active lupus nephritis in January 2021.